Skip to main content

Table 7 Predisposing effect of shared epitope genotypes on anticyclic citrullinated peptide antibody and rheumatoid factor seropositivity

From: HLA-DRB1 shared epitope genotyping using the revised classification and its association with circulating autoantibodies, acute phase reactants, cytokines and clinical indices of disease activity in a cohort of South African rheumatoid arthritis patients

  aCCP RF
SE groups OR (95% CI) Pvalue OR (95% CI) Pvalue
S1 (n = 24) 2.4 (1.1 to 5.4) 0.0113* 1.6 (0.9 to 2.9) 0.1245
S3D (n = 17) 2.3 (1.0 to 5.4) 0.0287* 1.7 (0.9 to 3.0) 0.1059
S1/S3D (n = 50) 2.3 (1.0 to 5.3) 0.0049** 1.6 (0.9 to 2.9) 0.0611
S2 (n = 11) 2.2 (0.9 to 5.2) 0.0995 1.6 (0.9 to 3.1) 0.1930
S3P (n = 28) 2.5 (1.1 to 5.6) 0.0075** 1.6 (0.9 to 3.0) 0.0563
S2/S3P (n = 47) 2.4 (1.1 to 5.5) 0.0025** 1.6 (0.9 to 2.8) 0.0687
  1. aCCP = anticyclic citrullinated peptide antibodies; RF = rheumatoid factor; SE = shared epitope. OR (95% CI) and P values were calculated using Fisher's exact test to compare rheumatoid arthritis patients with RA patients with the X/X genotype (n = 12). *P < 0.05. **P ≤ 0.008 values are highly significant. Groups S1, S3D, S2 and S3P consisted of the pooled homozygotes (SS) and heterozygotes (SX) for each group. Group S1/S3D consisted of S1/S1, S1/X, S3D/S3D, S3D/X and S1/S3D. Group S2/S3P consisted of S2/S2, S2/X, S3P/S3P, S3P/X and S2/S3P.